Societal CDMO (Societal CDMO) ROCE % : 6.26% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Societal CDMO ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Societal CDMO's annualized ROCE % for the quarter that ended in Dec. 2023 was 6.26%.

Societal CDMO ROCE % Historical Data

The historical data trend for Societal CDMO's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO ROCE % Chart

Societal CDMO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

20.51

-8.36

3.16

-3.32

-2.67

Societal CDMO Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-12.72	-7.45	-2.64	-5.18	6.26

Societal CDMO ROCE % Calculation

Societal CDMO's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.179	/	( ( (157.443 - 22.808)	+	(153.474 - 49.987) )	/ 2 )
	=	-3.179	/	( (134.635	+	103.487)	/ 2 )
	=	-3.179	/	119.061
	=	-2.67 %

Societal CDMO's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	7.3	/	( ( (151.53 - 21.623)	+	(153.474 - 49.987) )	/ 2 )
	=	7.3	/	( ( 129.907	+	103.487 )	/ 2 )
	=	7.3	/	116.697
	=	6.26 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Societal CDMO (NAS:SCTL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Societal CDMO ROCE % Related Terms

Thank you for viewing the detailed overview of Societal CDMO's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Societal CDMO (Societal CDMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (NAS:SCTL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341

Website

https://www.societalcdmo.com

Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.

Executives

Bryan M. Reasons	director	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Elena Cant	director	C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341
Enloe J David Jr	director, officer: Chief Executive Officer
James Charles Miller	director	490 LAPP ROAD, MALVERN PA 19355
Wayne Weisman	director	490 LAPP ROAD, MALVERN PA 19355
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Winston J Churchill	director	C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Mathew Paul Arens	director, 10 percent owner	C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
First Light Asset Management, Llc	director, 10 percent owner	3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
Laura L. Parks	director	C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355
Michael Berelowitz	director	415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016
Ryan David Lake	officer: Chief Financial Officer	KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Scp Vitalife Partners (israel) Ii, L.p.	10 percent owner	SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355
Scp Vitalife Partners Ii Lp	10 percent owner	SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355